Zynerba Pharmaceuticals Inc  

(Public, NASDAQ:ZYNE)   Watch this stock  
Find more results for ZYNE
11.45
+0.02 (0.17%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.15 - 11.50
52 week 5.42 - 25.95
Open 11.44
Vol / Avg. 159,893.00/319,016.00
Mkt cap 155.19M
P/E     -
Div/yield     -
EPS -2.59
Shares 13.55M
Beta     -
Inst. own 30%
Jan 4, 2018
Zynerba Pharmaceuticals, Inc. - Special Call - Webcast
Nov 28, 2017
Zynerba Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 14, 2017
Zynerba Pharmaceuticals Inc at Stifel Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -322600.10%
Operating margin - -320105.30%
EBITD margin - -319066.60%
Return on average assets -43.82% -58.33%
Return on average equity -49.07% -67.51%
Employees 12 -
CDP Score - -

Address

80 W. Lancaster Avenue, Suite 300
DEVON, PA 19333
United States - Map
+1-484-5817505 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Officers and directors

Armando Anido Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Terri B. Sebree President
Age: 59
Bio & Compensation  - Reuters
James E. Fickenscher Chief Financial Officer, Vice President - Corporate Development
Age: 53
Bio & Compensation  - Reuters
Suzanne M. Hanlon Secretary, General Counsel and Vice President, Human Resources
Age: 60
Bio & Compensation  - Reuters
William Roberts Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Ray Mannion Vice President - Manufacturing
Bio & Compensation  - Reuters
Brian Rosenberger Vice President - Commercial
Age: 48
Bio & Compensation  - Reuters
Liza Squires M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Warren D. Cooper M.D. Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
William J. Federici Independent Director
Age: 57
Bio & Compensation  - Reuters